| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Eugonia |
| Information provided by: | Eugonia |
| ClinicalTrials.gov Identifier: | NCT00415792 |
Purpose
hCG and GnRH agonist can be used to induce final oocyte maturation and ovulation in IVF cycles. These two approaches will be compared in this study in terms of pregnancy rates and embryological data using patients with hyper-response to IVF drugs.
| Condition | Intervention | Phase |
|
Infertility |
Drug: Arvekap, Pregnyl |
Phase IV |
| MedlinePlus related topics: | Infertility |
| ChemIDplus related topics: | Chorionic gonadotropin Choriogonadotropin Alfa Gonadorelin Gonadorelin hydrochloride LH-RH |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
| Official Title: | Administration of Human Chorionic Gonadotropin (hCG) Versus Gonadotropin Releasing Hormone (GnRH) Agonist for Ovulation Induction in Hyper-Responder Patients |
| Estimated Enrollment: | 60 |
| Study Start Date: | November 2003 |
| Estimated Study Completion Date: | July 2005 |
hCG is commonly used for the substitution of the endogenous LH surge to induce oocyte maturation and ovulation induction in ovarian hyperstimulation protocols for in vitro fertilization (IVF). However, hCG is related to the occurrence of the ovarian hyperstimulation syndrome (OHSS), a potentially life-threatening complication and hyper-responding patients are particularly in high risk. An alternative to exogenous hCG is the administration of a GnRH agonist inducing an endogenous rise in both LH and FSH levels due to the initial flare effect.
Comparisons: Pregnancy rates and embryological data will be compared from hyper-responding patients receiving either GnRH agonist (Arvekap) or hCG (Pregnyl) for ovulatrion induction following a GnRH antagonist treatment cycle.
Eligibility
| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations More Information
| Study ID Numbers: | arvekap vs pregnyl |
| First Received: | December 22, 2006 |
| Last Updated: | January 4, 2007 |
| ClinicalTrials.gov Identifier: | NCT00415792 |
| Health Authority: | Greece: National Organization of Medicines |
|
|
|
|
|
